In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Human Side of Viruses

Executive Summary

Immusol's business model today is different than when it started up in 1994. It's still doing gene transfer--only now into human cell lines, to see whether putting in ribozymes changes the cells' functions in therapeutically useful ways. The method has helped Immusol uncover two novel human genes that the Hepatitis C virus uses to replicate. Blocking these genes could block viral replication; Immusol aspires to find small molecules to do that. By targeting the human side of viral infection, the company may avoid the problems of viral mutation, and the patent estate of Chiron, which discovered and patented the cDNA for the Hepatitis C virus.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts